Hunter Capital provides additional information regarding the previously announced sale of the subsidiary Hunter Capital Dry Eye IPR to C100. This is stated in a press release.Hunter D-E IPR owns the Gel Effect patent portfolio, which includes technologies for the treatment of dry eye and contains both medical technology and pharmaceutical-related applications. The company's value is primarily linked to the intellectual property rights and future commercialization opportunities.As payment in the transaction, Hunter Capital receives 225.4 million newly issued shares in C100. After the transaction, Hunter Capital will own approximately 75.4 percent of the capital in C100, compared with 58.3 percent before the transaction.According to Hunter Capital, the transaction creates conditions for continued development of the patent portfolio while the company retains significant financial exposure to the asset's future value development.